Dual C-domain ACE / NEP Inhibitor

About AngioDesign

AngioDesign is a private, preclinical-stage biotech leveraging unique structural biology insights to develop next-generation, domain-selective ACE inhibitors. The company's founders were instrumental in solving the first high-resolution crystal structure of ACE, providing a foundation for designing drugs that aim to retain the cardiovascular benefits of traditional ACE inhibitors while mitigating common side effects like cough and angioedema. Its lead strategy involves developing first-in-class dual C-domain ACE/NEP inhibitors for hypertension and heart failure, targeting a blockbuster market with significant unmet need. The company operates with a lean management model and holds full ownership of its core intellectual property.

Therapeutic Areas